BERBERINE SULFATE ANHYDROUS

Possibly Marketed Outside US

First approved in 2023

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C20H18NO4.O4S
Molecular Weight	768.785
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BERBERINE SULFATE ANHYDROUS

Structure Search

SMILES

[O-]S([O-])(=O)=O.COC1=CC=C2C=C3C4=CC5=C(OCO5)C=C4CC[N+]3=CC2=C1OC.COC6=CC=C7C=C8C9=CC%10=C(OCO%10)C=C9CC[N+]8=CC7=C6OC

InChI

InChIKey=OJVABJMSSDUECT-UHFFFAOYSA-L

InChI=1S/2C20H18NO4.H2O4S/c2*1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2;1-5(2,3)4/h2*3-4,7-10H,5-6,11H2,1-2H3;(H2,1,2,3,4)/q2*+1;/p-2

HIDE SMILES / InChI

Molecular Formula	O4S
Molecular Weight	96.063
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H18NO4
Molecular Weight	336.3612
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.webmd.com/vitamins-supplements/ingredientmono-1126-berberine.aspx?activeingredientid=1126&activeingredientname=berberine
Curator's Comment: description was created based on several sources, including: https://examine.com/supplements/berberine/ | https://www.ncbi.nlm.nih.gov/pubmed/19686830 | https://www.ncbi.nlm.nih.gov/pubmed/25610485

Berberine, an alkaloid isolated from Rhizoma Coptidis, is known to have a wide array of therapeutic effects including antimicrobial, antineoplastic, and hepatoprotective effects. It is found in several plants including European barberry, goldenseal, goldthread, Oregon grape, phellodendron, and tree tumeric. Berberine seems to slightly reduce blood sugar levels in people with diabetes. Berberine might lower blood pressure. Berberine is possibly safe for most adults for short-term use when taken by mouth or applied to the skin.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase I 60 Target ID: CHEMBL1781 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19686830	Inhibitor 8504
cell cycle arrest 14 Target ID: GO:0007050 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19686830	Activator 1447
Apoptosis 156 Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19686830	Activator 1447

Conditions

Condition	Modality	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: https://examine.com/supplements/berberine/	Primary	Phase III 665	Unknown Approved Use Unknown
Colorectal adenoma 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26397137	Primary	Phase III 665	Unknown Approved Use Unknown
Ulcerative colitis 125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27587080	Primary	Phase IV 63	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
0.33 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30587933/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		BERBERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.99 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30587933/	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BERBERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
6.28 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30587933/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		BERBERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
38.74 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30587933/	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BERBERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
30.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30587933/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		BERBERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
33.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30587933/	300 mg 1 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered:		BERBERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
500 mg 3 times / day steady, oral Highest studied dose Dose: 500 mg, 3 times / day Route: oral Route: steady Dose: 500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18442638/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/18442638/	Disc. AE: gastrointestinal disorders... AEs leading to discontinuation/dose reduction: gastrointestinal disorders (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/18442638/
300 mg 3 times / day steady, oral Studied dose Dose: 300 mg, 3 times / day Route: oral Route: steady Dose: 300 mg, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/results/NCT02365480?term=berberine&rslt=With&draw=2&rank=1; https://storage.googleapis.com/ctgl-large-docs/80/NCT02365480/Prot_SAP_000.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://clinicaltrials.gov/ct2/show/results/NCT02365480?term=berberine&rslt=With&draw=2&rank=1; https://storage.googleapis.com/ctgl-large-docs/80/NCT02365480/Prot_SAP_000.pdf	Sources: https://clinicaltrials.gov/ct2/show/results/NCT02365480?term=berberine&rslt=With&draw=2&rank=1; https://storage.googleapis.com/ctgl-large-docs/80/NCT02365480/Prot_SAP_000.pdf

AEs

AE	Significance	Dose	Population
gastrointestinal disorders	4 patients Disc. AE	500 mg 3 times / day steady, oral Highest studied dose Dose: 500 mg, 3 times / day Route: oral Route: steady Dose: 500 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/18442638/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/18442638/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
activator 150 inhibitor 2252 substrate 1946	substrate 1193	inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP1A1 132 CYP1B1 32 OATP1B1 1079 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 OATP1B3 961 OATP2B1 157 OCT2 779 OCT1 620	CYP2C19 1119 CYP2B6 776 CYP2A6 626 P-gp 2052 CYP1A2 1197 CYP2E1 729 CYP2C8 810 OCT1 393 MATE1 182 MRP2 252 OCT2 434 MRP1 113	CYP1A1 151 CYP1A2 832 CYP1B1 71 P-gp 301

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19	no [IC50 >10 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19 \| https://pubmed.ncbi.nlm.nih.gov/21870106/	no [IC50 >10 uM]	no (co-administration study) Comment: Berberine (300mg, TID x 2w) decreased caffeine Cmax by 88% and AUCinf by 85%. Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19 \| https://pubmed.ncbi.nlm.nih.gov/21870106/
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19 \| https://pubmed.ncbi.nlm.nih.gov/21870106/	no [IC50 >10 uM]	no (co-administration study) Comment: Berberine (300mg, TID x 2w) decreased omeprazole Cmax by 99% and AUCinf by 98%. Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19 \| https://pubmed.ncbi.nlm.nih.gov/21870106/
CYP3A4 2633	activator 342 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTIwODkifX0=	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI5NTEyNCJ9fQ==	weak [Inhibition 20 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI5NTEyNCJ9fQ==	weak [Inhibition 20 uM]
OATP2B1 162	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI0IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI5NTEyNCJ9fQ==	weak [Inhibition 20 uM]
CYP1B1 93	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0ODc4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDI5NTEyNCJ9fQ==	yes [IC50 0.094 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25359200/	yes [IC50 11.28 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTIwODkifX0= \| https://pubmed.ncbi.nlm.nih.gov/21870106/	yes [IC50 12.5893 uM]	yes (co-administration study) Comment: Berberine (300mg, TID x 2w) increased midazolam Cmax by 138% and AUCinf by 140%. Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTIwODkifX0= \| https://pubmed.ncbi.nlm.nih.gov/21870106/
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTIwODkifX0= \| https://pubmed.ncbi.nlm.nih.gov/21870106/	yes [IC50 4.5042 uM]	yes (co-administration study) Comment: Berberine (300mg, TID x 2w) increased urinary dextromethorphan/dextrorphan ratio by 979%. Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTIwODkifX0= \| https://pubmed.ncbi.nlm.nih.gov/21870106/
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25359200/	yes [IC50 7.28 uM]
CYP1A1 272	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyMjMxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19	yes [Inhibition 10 uM]
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/24528081/	yes
CYP1A2 2333	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/28893642/	yes
CYP1B1 93	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/24528081/	yes
P-gp 1932	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/29891588/	yes

Drug as victim

Target	Modality	Activity
CYP2D6 1388	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	major
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	minor
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	minor
CYP2E1 729	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	minor
CYP3A4 1946	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	minor
CYP2A6 626	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	no
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	no
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	no
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/21787170/	no
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/26634613/	no
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18157518/	yes [Km 14.8 uM]
MATE1 182	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/28298174/	yes [Km 4.28 uM]
OCT2 434	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18157518/	yes [Km 4.4 uM]
MRP1 113	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/17213652/	yes
P-gp 2052	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyMDg5In19	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTIwODkifX0= \| https://pubmed.ncbi.nlm.nih.gov/29143794/

PubMed

Title	Date	PubMed
Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/β-catenin signaling pathway.	2016-01-05	26478571
Kinetics and molecular docking studies of cholinesterase inhibitors derived from water layer of Lycopodiella cernua (L.) Pic. Serm. (II).	2015-10-05	26297990
The neuroprotective effect of berberine in mercury-induced neurotoxicity in rats.	2015-08	25600690
Berberine protects liver from ethanol-induced oxidative stress and steatosis in mice.	2014-12	25455889
Multiple mechanisms of cell death induced by chelidonine in MCF-7 breast cancer cell line.	2014-11-05	25265580
The potential effect of berberine in mercury-induced hepatorenal toxicity in albino rats.	2014-07	24751971
Palmatine activates AhR and upregulates CYP1A activity in HepG2 cells but not in human hepatocytes.	2014-06	24583342
Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth.	2013-11-01	23954465
Mechanism study of goldenseal-associated DNA damage.	2013-07-31	23747414
Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: a biphasic experimental study.	2013-05-23	23523906
Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling.	2012-12	23363784
Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine.	2012-08	22775417
Structure-activity studies of some berberine analogs as inhibitors of Toxoplasma gondii.	2012-04-15	22425568
Modulations of cytochrome P450 expression in diabetic mice by berberine.	2012-03-05	22342832
The formation and stabilization of a novel G-quadruplex in the 5'-flanking region of the relaxin gene.	2012	22363579
Berberine down-regulates the Th1/Th2 cytokine gene expression ratio in mouse primary splenocytes in the absence or presence of lipopolysaccharide in a preventive manner.	2011-12	21867779
Berberine protects against lipopolysaccharide-induced intestinal injury in mice via alpha 2 adrenoceptor-independent mechanisms.	2011-11	21963898
Antitumor effects of the combination of cholesterol reducing drugs.	2011-07	21491092
Characterization of protoberberine analogs employed as novel human P2X7 receptor antagonists.	2011-04-15	21320518
Effect of traditional Chinese medicinal herbs on Candida spp. from patients with HIV/AIDS.	2011-04	21441482
Synthesis of 9-substituted derivatives of berberine as anti-HIV agents.	2011-04	21295891
Berberine attenuates lipopolysaccharide-induced impairments of intestinal glutamine transport and glutaminase activity in rat.	2011-04	21073932
Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.	2011-03	20828602
Hepatoprotective activity of berberine is mediated by inhibition of TNF-α, COX-2, and iNOS expression in CCl(4)-intoxicated mice.	2011-02-04	21095217
Anti-herpes simplex virus effects of berberine from Coptidis rhizoma, a major component of a Chinese herbal medicine, Ching-Wei-San.	2010-12	20686799
Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells.	2010-12	20564506
Cytotoxicity of berberine on human cervical carcinoma HeLa cells through mitochondria, death receptor and MAPK pathways, and in-silico drug-target prediction.	2010-09	20656010
Berberine suppresses intestinal disaccharidases with beneficial metabolic effects in diabetic states, evidences from in vivo and in vitro study.	2010-04	20229011
[Controlling effect of berberine on in vitro synthesis and metabolism of steroid hormones in insulin resistant ovary].	2010-02	20462044
Effect of berberine on the antioxidant status, ultrastructural modifications and protein bound carbohydrates in azoxymethane-induced colon cancer in rats.	2009-02-12	18951886
Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus.	2008-11-05	19080170
Combination of simvastatin with berberine improves the lipid-lowering efficacy.	2008-08	18640378
Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula.	2008-07-23	18501540
Effect of berberine on expression of hepatocyte nuclear factor-4alpha in rats with fructose-induced insulin resistance.	2008-06	18563319
Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors.	2008-03	17973934
Studies on alkaloids binding to GC-rich human survivin promoter DNA using positive and negative ion electrospray ionization mass spectrometry.	2008-03	17968851
Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide.	2008-02-25	18294404
Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells.	2006-02	16505103
Effect of berberine on interleukin 8 and monocyte chemotactic protein 1 expression in a human retinal pigment epithelial cell line.	2006	16391493
Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system.	2005-11	16122816
Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: Biphasic effect on CYP1A1.	2005-09-15	16046213
Search of chemical scaffolds for novel antituberculosis agents.	2005-04	15809316
Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus.	2005	16379555
[The interaction of berberine and human serum albumin].	2004-01	15768991
The effect of Kampo formulae on bone resorption in vitro and in vivo. I. Active constituents of Tsu-kan-gan.	1998-12	9881647
Antitubercular natural products: berberine from the roots of commercial Hydrastis canadensis powder. Isolation of inactive 8-oxotetrahydrothalifendine, canadine, beta-hydrastine, and two new quinic acid esters, hycandinic acid esters-1 and -2.	1998-10	9784149
Screening of compounds for antimicrosporidial activity in vitro.	1998	9684323
Effect of long-term administration of berberine on scopolamine-induced amnesia in rats.	1997-07	9268086
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.	1991-01-01	1710653
Screening for new compounds with antiherpes activity.	1984-10	6517562

Patents

Sample Use Guides

In Vivo Use Guide

500 mg of berberine 2-3 times daily for up to 3 months

Route of Administration: Oral

In Vitro Use Guide

Berberine acted cytotoxically on both tumour cell lines. The melanoma B16 cells were much more sensitive to berberine treatment than the U937 cells. The value of IC(100) was below 100 ug/ml for the U937 cells and below 1 ug/ml for the B16 cells. As for both cell lines under the long-term influence the values of IC(50) were found to be less than 4 ug/ml.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:24:23 GMT 2025` Edited by `admin` on `Mon Mar 31 18:24:23 GMT 2025`
Record UNII	FST3E667FF
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BERBERINE SULFATE

Preferred Name

English

BERBERINE SULFATE ANHYDROUS

Common Name

English

ERBEN

Brand Name

English

5,6-DIHYDRO-9,10-DIMETHOXYBENZO(G)-1,3-BENZODIOXOLO(5,6-A)QUINOLIZINIUM SULPHATE

Common Name

English

BERBERINE SULFATE [HSDB]

Common Name

English

BENZO(G)-1,3-BENZODIOXOLO(5,6-A)QUINOLIZINIUM, 5,6-DIHYDRO-9,10-DIMETHOXY-, SULFATE (2:1)

Common Name

English

BERBERINE SULFATE (2:1)

Common Name

English

Berberine sulfate [WHO-DD]

Common Name

English

NEUTRAL BERBERINE SULFATE

Common Name

English

5,6-DIHYDRO-9,10-DIMETHOXYBENZO(G)-1,3-BENZODIOXOLO(5,6-A)QUINOLIZINIUM SULFATE

Common Name

English

BERBERINE SULPHATE

Common Name

English

NSC-5355

Code

English

Code System Code Type Description

SMS_ID

100000077186